CD133+ RCC cells did not show in vivo tumorigenic capability, but when co-transplanted with RCC cells, they enhanced tumor engraftment, vascularization, and growth; however, different results have been obtained subsequently [86,87]. The gene discussed is PROM1; the disease is neoplasm.